Metastatic endometrial cancer in lung and liver: complete and prolonged response to hormonal therapy with progestins

Gynecol Oncol. 1999 Feb;72(2):250-5. doi: 10.1006/gyno.1998.5229.

Abstract

A double complete and prolonged response of metastatic endometrial carcinoma to medroxyprogesterone is reported. A 61-year-old woman with metastatic endometrial carcinoma in lung and liver achieved a complete clinical response with medroxyprogesterone lasting for 2 years. She discontinued the therapy by herself and developed a pulmonary relapse, which disappeared after retreatment with the same hormonal therapy. At present, she is alive without evidence of disease 6 years after starting progestins for metastatic disease and 14 years after treatment of the primary tumor. Progestin therapy in metastatic endometrial carcinoma is discussed, emphasizing the factors predicting response.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma / drug therapy
  • Carcinoma / secondary*
  • Endometrial Neoplasms / drug therapy
  • Endometrial Neoplasms / pathology*
  • Female
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary*
  • Medroxyprogesterone / therapeutic use*
  • Middle Aged
  • Progesterone Congeners / therapeutic use*
  • Tomography, X-Ray Computed

Substances

  • Progesterone Congeners
  • Medroxyprogesterone